Cellsion wins a prize in the Japan Semi-Final


Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a deep tech start-up developing iPS cell-derived corneal endothelial cell substitute for the treatment of bullous keratopathy, announced that the company has been selected as one of the winning companies in the Japan semi-final of “the JINJI LAKE STARTUP CONTEST JAPAN 2023,” organized by the Talent Bureau of the Organization Department of China and co-organized by AIS CAPITAL Corporation and the Suzhou Industrial Park International Business Cooperation Center (Tokyo).

Launched in 2012, the JINJI LAKE STARTUP CONTEST is one of the most influential global business competitions in China that attracts some of the best startups within and beyond China.
Of the more than 200 companies that have made it to the finals in past competitions, more than 100 have raised funds, totaling approximately 2 billion US dollars.

This year’s Japan semi-final was held on August 25, and our EVP & COO, Dr. Hayashida, participated. In his presentation, he explained the progress of R&D and future business expansion, and as a result of the screening process, Cellusion was awarded a prize.

Via the industry final competition, the six companies that made it through to the Japan semi-final will be invited to participate in the final competition to be held in Suzhou in November together with finalists selected from around the world.
The contest participants have the opportunity to interact with industry experts through feedback and mentoring sessions. Furthermore, the startup companies will gain extensive exposure to various VC funds and angel investors.

For more information, please visit the link below

[About Cellusion]
Cellusion is a regenerative medicine start-up originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN
Founded: January 2015

For further information: please ask us through the contact form on our website.

Back to the List